a couple of very interesting announcements this week.
so we knew from the quarterly that David and team secured the new SII order and set up the meeting.
the question raised is an extra $213k order on the minimum spend, enough to warrant a visit by SII's executive?
its also excellent that anteo have told the market about the delay in the executive visit and a regulatory delay with vidcare.
with vidcare the relationship has grown to future tests and particle qualification with NXT
the next question raised, does these announced deals in India warrant the plans for 3 staff to be positioned in India in the next year. so what does warrant it?
lastly the Koma prototype assay development program. merrill has been CEO for roughly 8 weeks. was this deal initiated by the previous management? if not in 8 weeks the new team has nutted out the deal and the lab guys have completed development of a prototype lateral flow assay device and delivered it a very quick turnaround. that would be from expertise gained from years of development work if it was.
also the $17.5K shows that new development work will be paid for as suggested. a good development
GLTAH
interesting times
ADO Price at posting:
0.9¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)